Navigation Links
Solos Endoscopy Finishes the 3rd Quarter Strong

BOSTON, Oct. 21, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40.  The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company recently announced its intentions to donate 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.

About Solos Endoscopy, Inc.:Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.CONTACT:


SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
2. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
3. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
4. Solos Endoscopy to Reduce Debt by Over $620,000
5. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
6. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
7. Solos Endoscopy, Inc. To Launch New Corporate Website
8. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
9. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
10. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
11. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor ... application server to improve system efficiency and reliability. , The new Q-Suite 6 platform ... standards, the system avoids locking itself into a specific piece of software for many ...
Breaking Medicine News(10 mins):